Brief: Aligos Therapeutics Initiates Dosing In Healthy Volunteers With Sirna Drug Candidate ALG-125755
14/10/2022 13:07
Oct 14 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS INITIATES DOSING IN HEALTHY VOLUNTEERS
WITH
SIRNA DRUG CANDIDATE ALG-125755
* ALIGOS THERAPEUTICS INC - SINGLE ASCENDING DOSES TO BE
EVALUATED
IN SUBJECTS WITH CHRONIC HEPATITIS B BEGINNING IN Q1 2023
* ALIGOS THERAPEUTICS INC - SINGLE ASCENDING DOSES TO BE
EVALUATED
IN HEALTHY VOLUNTEERS IN Q4 2022
Source text for Eikon: ID:nGNX3bPqvs
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue